The DOI matches its Crossref record; 17 of the 19 references it cites were found in a registry or an index; 4 of the 14 sources its claims cite were checked for support.
Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty
Open accessAbstract
Precocious puberty, characterised by the early appearance of secondary sexual characteristics, poses challenges in diagnosis and management. Here, we describe a case of precocious puberty diagnosed in a boy in middle childhood, who presented with progressive phallus enlargement, pubic hair development and increased aggressive behaviour. Hormonal evaluation confirmed the diagnosis of congenital adrenal hyperplasia (CAH), complicated by gonadotropin-dependent precocious puberty. The case highlights the importance of assessment of testicular volume in a patient presenting with precocious puberty. Symmetrical testicular enlargement in a patient with CAH suggests premature activation of the hypothalamic-pituitary-gonadal axis. The patient received glucocorticoid therapy to suppress androgen production related to CAH and gonadotropin-releasing hormone analogue therapy to control premature activation of the hypothalamic-pituitary-gonadal axis. Follow-up visits showed regression of secondary sexual characteristics and improved growth velocity.
Overview
CoChat Summary
TL;DR
This case report describes a boy in middle childhood with congenital adrenal hyperplasia (CAH) due to 21α-hydroxylase deficiency who developed gonadotropin-dependent precocious puberty (GDPP). Combined hydrocortisone and gonadotropin-releasing hormone agonist therapy led to regression of secondary sexual characteristics and improved growth velocity.
Key findings
- The patient presented with progressive phallus enlargement for 1.5 years, pubic hair, voice deepening, and increased aggressive behaviour; examination showed height 134.6 cm (Z score +2.3), weight 26 kg (Z score +0.9), phallus 10×3 cm, Tanner stage 4 pubic hair, and bilateral testicular volume 5 mL.
- Endocrine evaluation showed testosterone 7.9 nmol/L (pre-pubertal normal <0.7), basal LH 1.1 IU/L (normal 0.02–0.3), stimulated LH 15.3 IU/L (normal <5), and 17-OHP 338.9 nmol/L (normal <3.03), confirming classic CAH with superimposed GDPP; bone age was 11 years.
- Treatment with hydrocortisone 10 mg/day (10 mg/m²/day) in three divided doses and leuprolide depot 3.75 mg monthly, later changed to 11.25 mg every 3 months, produced regression of secondary sexual characteristics and improved growth velocity.
- At 12-month follow-up, testosterone had fallen from 7.9 to 0.5 nmol/L and 17-OHP from 338.9 to 15.7 nmol/L; basal and stimulated LH declined to pre-pubertal range, and fludrocortisone 50 µg/day was added at 9 months.
Methods
- Single case report of a boy in middle childhood referred to endocrinology with signs of precocious puberty.
- Diagnostic workup included physical examination, hormone assays (testosterone, LH basal and leuprolide-stimulated, 17-OHP, cortisol, ACTH, thyroid function, electrolytes, β-hCG), bone age, scrotal ultrasound, and brain MRI.
- Descriptive analysis of baseline and serial follow-up biochemical parameters over 12 months after combined hydrocortisone and GnRHa therapy.
Limitations
- The paper states that financial constraints and lack of testing facilities prevented assessment of the mineralocorticoid axis, including plasma renin and aldosterone.
- The text notes that case reports should not be used in isolation to guide treatment choices or public health policy.
- Evident from the text: this is a single-patient report with no control group, so findings are not generalisable and treatment outcomes cannot be attributed with certainty to the intervention alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 9 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In such settings, delays in seeking treatment and initiating GnRHa therapy may adversely affect height outcomes in CAH with GDPP.”
What the sources say
- Supportedcites [15] Dayal, 2018, Central precocious puberty complicating congenital adrenal hyperplasia: North Indian experience, Indian J Endocrinol Metab source
In the ‘Sir’ section (p. 1), the authors report that their patients’ mean delay in seeking treatment exceeded one year and probably caused substantial bone-age advancement. They explicitly conclude that delays in diagnosis and initiation of GnRHa therapy adversely affect height outcomes in CAH complicated by central precocious puberty in resource-limited settings. (LLM, conf=0.94)
hedgedstates a possible causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Hydrocortisone is the preferred glucocorticoid in children with CAH owing to its short half-life and the fact that it has minimal impact on the growth plate.4”
What the sources say
- Supportedcites [4] Mallappa, 2022, Management challenges and therapeutic advances in congenital adrenal hyperplasia, Nat Rev Endocrinol source
The Glucocorticoid therapy section says hydrocortisone is preferred in children with CAH because of its short half-life and the lowest growth-suppressing effect among available glucocorticoids. This supports the citing sentence’s paraphrase about its effect on growth. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with simple virilising CAH due to 21α-hydroxylase deficiency have 1–5% residual enzymatic activity, sufficient to prevent the salt-wasting crisis.”
What the sources say
- Partly supportedcites [4] Mallappa, 2022, Management challenges and therapeutic advances in congenital adrenal hyperplasia, Nat Rev Endocrinol sourceExperimental — accuracy not yet measured
The Introduction (page not available) says simple virilizing CAH retains <5% enzyme activity and some ability to make aldosterone, in contrast to salt-wasting CAH, which can cause an early adrenal crisis. It does not give a 1–5% range. The Mineralocorticoid therapy section (page not available) adds that aldosterone production in simple virilizing CAH is often insufficient to maintain normal intravascular volume, so the claim of sufficient activity to prevent a salt-wasting crisis is too categorical. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [5] Bhansali A , Aggarwal A , Parthan G , et al . Congenital adrenal hyperplasia. In: Clinical rounds in endocrinology, 2. 2016: 335–76. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Basal and stimulated LH declined to the pre-pubertal range.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient's elevated serum testosterone levels indicated the presence of precocious puberty.”
hedgedstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
9 more claims
Create a free account to see all 24 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 1
Citations
Cites
Carel, J.-C., & Léger, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0800459 · Cited by 761
Dumitrescu, C. E., & Collins, M. T. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-12 · Cited by 454
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Treatment and Outcomes of Precocious Puberty: An Update
Fuqua, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1024 · Cited by 260
Adult Height in Patients with Congenital Adrenal Hyperplasia: A Systematic Review and Metaanalysis
Muthusamy, K., Elamin, M. B., Smushkin, G., Murad, M. H., Lampropulos, J. F., Elamin, K. B., Abu Elnour, N. O., Gallegos-Orozco, J. F., Fatourechi, M. M., Agrwal, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2616 · Cited by 182
Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.002 · Cited by 177
Pescovitz, O. H., Comite, F., CASSORLA, F. G., Dwyer, A. J., Poth, M., Sperling, M. A., HENCH, K. D., McNEMAR, A., SKERDA, M. C., Loriaux, D. L., et al. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-5-857 · Cited by 147
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Güven, A., Cebeci, A. N., & Hancili, S. (2015) · HORMONES · doi:10.14310/horm.2002.1555 · Cited by 39
Stretched Penile Length and Testicular Size from Birth to 18 Years in Boys from Western Maharashtra
Khadilkar, A., Jaiswal, V., Khadilkar, V., & Lohiya, N. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_242_18 · Cited by 22
Cited by
Precocious puberty: the unlikely herald of Familial adenomatous polyposis in a young girl
Karthik, V., Jabbar, P. K., Alam, A., & Nair, A. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-263412
Self-citationClassic Congenital Adrenal Hyperplasia Presenting as Primary Amenorrhea
Karthik, V., Salman, M., & Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_3_26
Self-citation
Metadata
- Authors
- Alam, A., Agrawal, N. K., & Singh, S. K.
- Affiliations
- Aligarh Muslim University (IN)
- Institute of Medical Sciences (IN)
- Corresponding author
- Alam, Ahmad
- Venue
- BMJ Case Reports
- Publisher
- BMJ
- Published
- 2024-03
- Volume
- 17
- Issue
- 3
- Pages
- e257579
- ISSN
- 1757-790X (ISSN-L)
- PMC
- PMC11107083
- OpenAlex
- W4392466683
- Semantic Scholar
- 0edcf54a7b718886002b9c17ac75e69d1f6cc5bf
- Cited by
- 2
- References
- 19
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- BMJ Case Reports (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- congenital adrenal hyperplasia, precocious puberty, testicular enlargement, hypothalamic-pituitary-gonadal axis, glucocorticoid therapy, GnRH analogues, secondary sexual characteristics, pubic hair development, aggression, growth rate
- MeSH terms
- Adrenal Hyperplasia, Congenital, Aggression, Child, Gonadotropins, Humans, Male, Puberty, Precocious, Abdominal Wall
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty. https://app.cochat.ai/papers/10.1136/bcr-2023-257579
- The paper
- Alam, A., Agrawal, N. K., & Singh, S. K. (2024). Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty. BMJ Case Reports. https://doi.org/10.1136/bcr-2023-257579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.